Search

Displaying results 1321 - 1330 of 2160 in total
  1. Drug

    Recombinant stabilized RSV B prefusion F antigen

    go.drugbank.com/drugs/DB18714
    ApprovedInvestigational

    [L49555] Abrysvo was approved for the same indications in the EU in August 2023[L49565] and Canada in December 2023.

  2. Drug

    Fish oil

    go.drugbank.com/drugs/DB13961
    ApprovedInvestigationalNutraceutical

    Fish oil is a component of SMOFLIPID, which was FDA approved in July 2016. It is indicated in adults as a source of calories and essential fatty acids for parenteral nutrition when oral or enteral nutrition is not possible, insufficient,...

    Mixtures: SMOFKABIVEN EF, Shine Fish Oil + Natural Vitamin E
  3. Drug

    SW033291

    go.drugbank.com/drugs/DB32765
    Experimental

    [A275473, A275474] It has been found to increase prostaglandin E2 (PGE2) and is being investigated in accelerating of hematopoietic recovery and treating type 2 diabetes mellitus.[A275473, A275474]

  4. Drug

    Dorzolamide

    go.drugbank.com/drugs/DB00869
    ApprovedInvestigational

    Dorzolamide is a non-bacteriostatic sulfonamide derivative and topical carbonic anhydrase (CA) inhibitor that treats elevated intraocular pressure (IOP) associated with open-angle glaucoma and ocular hypertension. It works by blocking an...

    Mixtures: DORZOLAMIDE E TIMOLOLO EG, DORZOLAMIDE E TIMOLOLO EGCategories: Genito Urinary System and Sex Hormones
  5. Drug

    Iberdomide

    go.drugbank.com/drugs/DB12101
    Investigational

    [L64055,L64056] It is the first cereblon E3 ligase modulator (CELMoD) approved for multiple myeloma.[L64057] … [L64055] It binds cereblon, the substrate-recognition component of an E3 ubiquitin ligase complex, and drives the ubiquitination and proteasomal degradation of the transcription factors Aiolos and Ikaros

    Categories: Cereblon E3 ligase modulator
  6. Drug

    IR208

    go.drugbank.com/drugs/DB05106
    Investigational

    It contains three peptides (BV5S2, BV6S5 and BV13S1) expressed by T-Cells in over 90% of MS patients. IR208 is currently undergoing Phase II studies in a 200-patient trial.

  7. Drug

    JSM 6427

    go.drugbank.com/drugs/DB06139
    Investigational

    It has been biologically validated for therapeutic use in the prevention and treatment of wet AMD, the leading cause of blindness in people over the age of 55.

  8. Drug

    1-Dodecanol

    go.drugbank.com/drugs/DB06894
    Experimental

    (From McGraw-Hill Dictionary of Scientific and Technical Terms, 5th ed)

  9. Drug

    Rintodestrant

    go.drugbank.com/drugs/DB21472
    Investigational

    Rintodestrant is under investigation in clinical trial NCT03455270 (G1T48, an Oral SERD, Alone and in Combination With Palbociclib in ER-Positive, HER2-Negative Advanced Breast Cancer).

  10. Drug

    Taragarestrant

    go.drugbank.com/drugs/DB21574
    Investigational

    Taragarestrant is under investigation in clinical trial NCT06954961 (A Study to Evaluate D-0502 in Subjects With ER+ Her2- Locally Advanced or Metastatic Breast Cancer).